Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Condition: Type 2 Diabetes Mellitus Interventions: Drug: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010); Drug: INSULIN GLARGINE (HOE901); Drug: Metformin; Drug: Insulin Glulisine (HMR1964) Sponsor: Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | India Health | Insulin | Lantus | Metformin